Annual Report to Shareholders
Released
Released
Announcement PDF
Pharmaceuticals
ASX: RCE, FSE: R9Q
20
25
Annual Report
About Us
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is
an Australian late-stage clinical biotech company
focused on the development and commercialisation
of a new class of Synthetic Anti-infectives designed
to address the urgent global health problem of
antimicrobial resistant (AMR) superbugs.
Recce’s lead candidate, RECCE® 327 (R327), is a
patented, broad-spectrum synthetic anti-infective
being developed in multiple formulations, including
intravenous and topical. It is designed to treat
serious bacterial infections, including those caused
by drug-resistant Gram-positive and Gram-negative
pathogens.
R327 as a Topical Gel (R327G) is currently
undergoing Phase 3 clinical development, with
a particular focus on addressing diabetic foot
infections (DFIs), a major complication of diabetes
and a significant global health burden. Recce is also
advancing a broader portfolio of synthetic antiinfectives targeting a range of unmet medical
needs across bacterial infections.
The Company’s lead clinical program involves a
registrational Phase 3 clinical trial of R327G for
the treatment of DFIs, conducted in Indonesia.
The Indonesian trial is designed to generate pivotal
safety and efficacy data and serves as a potential
gateway to broader regulatory and commercial
opportunities across the ASEAN market.
The Company also has a Cooperative Research
and Development Agreement with US Army Medical
Research Institute of Infectious Diseases, to evaluate
R327 against biothreat pathogens targeting burn
wound infections.
Recce’s fully owned, automated manufacturing
facility in Australia supports ongoing clinical
development and scale-up. With a strong global
portfolio of patents protecting its intellectual
property beyond 2040 and a focus on unmet
medical needs in diabetic wound care, Recce is
advancing a next-generation anti-infective platform
poised for near-term commercialisation and global
expansion.
Contents
Business Highlights
Letter from Chairman
Letter from CEO
Overview of Company Activities
Topical Programs
Intravenous Programs
Preclinical
Conference Engagement
Financial Report
Corporate Directory
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
Board of Directors and
Management Personnel
2
4
6
8
9
12
13
14
16
19
78
1
Business
Highlights
Listed below are the main company developments for the 2025 Financial Year.
Clinical and Preclinical
Diabetic Foot Infections (DFI)/Acute Bacterial Skin and
Skin-Structure Infections (ABSSSI)
Phase 3 Registrational Clinical Trial for DFI in Indonesia
•
Human Research Ethics Committee approval received for Registrational Phase
3 Clinical Trial for RECCE® 327 Topical Gel (R327G) in patients with
DFI in Indonesia.
•
Regulatory approval received for Registrational Phase 3 Clinical Trial for R327G.
Phase II ABSSSI Clinical Trial in Australia
•
Phase II ABSSSI clinical trial patient dosing completed and positive patient
data released.
•
Phase II Clinical Trial data successfully demonstrated R327G achieving a
93% primary efficacy endpoint over 14-days, meeting all study endpoints.
• Phase II Clinical Trial receives approval for additional diabetic patients to be
treated with R327G.
Urinary Tract Infection (UTI)/Urosepsis
• Recce is proceeding with plans for a proposed Phase II clinical trial in Australia
to be launched in FY26.
Preclinical
• Positive Efficacy Data from Murdoch Children’s Research Institute in Study
against WHO Priority Pathogen Acinetobacter baumannii.
• R327 efficacy validated against Mycobacterium abscessus, a non-tuberculous
mycobacteria (NTM) that causes lung infections in cystic fibrosis and
immunocompromised patients.
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
2
U.S. Department of Defense Burn Wound Program
• U.S. Department of Defense Grants Recce Pharmaceuticals US$2 million
to accelerate development of RECCE® 327 Gel (R327G) for acute treatment
of burn wound infections and downstream bacteria complications such as
sepsis in military setting.
• Recce Enters into Defense Threat Reduction Agency (DTRA) Backed
Cooperative Research & Development Agreement with United States Army
Medical Research Institute of Infectious Diseases (USAMRIID) to test RECCE®
327 (R327) against highly hazardous pathogens of biodefense concern in
USAMRIID under high biocontainment conditions.
Commercial and Operational
•
Successful A$15.8 million capital raise - all from existing shareholders.
•
Non-Dilutive Financing via debt facility of up to ~A$30 million with
Avenue Capital Group.
•
Canadian Scientific Research & Experimental Development Rebate of
US$175,122 (A$271,987) from the Canadian Government received.
Regulatory
•
Family 3 patent granted for RECCE® Anti-Infectives in Australia,
expiring in 2037.
•
Family 4 patent granted for RECCE® Anti-Infectives in Japan,
expiring in 2041.
•
Family 4 patent granted for RECCE® Anti-Infectives in China,
expiring in 2041.
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
3
Letter from
the Chairman
Dear Shareholders,
We are pleased to present Recce Pharmaceuticals’
annual report for the financial year ended June
2025. This year has been one of progress across
clinical, regulatory, and strategic fronts, reflecting
the strength of our synthetic anti-infective platform
and the dedication of our team, and placing Recce
at the forefront of the anti-infective market. These
developments strengthen our position as a leader in
the fight against antimicrobial resistance, coinciding
with renewed and significant interest highlighted by
some notable acquisitions over the last 12 months.
Our work remains focused on
delivering bold, science-driven
solutions to address this
challenge for those who
need it most.
Clinical and Preclinical Milestones Achieved
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
4
Recce’s pipeline of synthetic anti-infective
compounds continues to advance rapidly, with key
achievements across multiple programs in 2025.
A standout achievement was the approval we
received for our Phase 3 Registrational Clinical
Trial for R327G in Diabetic Foot Infections (DFI) in
Indonesia. This included receiving Human Research
Ethics Committee approval and full regulatory
clearance to proceed from Indonesia’s National
Agency of Drug and Food Control (Badan POM),
marking a critical step toward potential market
registration of R327G in CY2026.
In parallel, our Phase II Acute Bacterial Skin and
Skin Structure Infections (ABSSSI) clinical trial
reached a major milestone with the successful
completion of patient dosing and release of strong
clinical data. Indeed, R327G demonstrated a 93%
primary efficacy endpoint over 14 days, meeting all
predefined study endpoints. Notably, the trial also
received approval to include additional diabetic
patients, further extending the clinical scope and
real-world application of R327G.
Further international recognition came through
the commencement of our collaboration with the
U.S. Department of Defense (DoD). Recce was
not only awarded a USD$2 million grant under the
DoD’s Burn Wound Program, but we also entered a
Cooperative Research and Development Agreement
(CRADA) with the U.S. Army Medical Research
Institute of Infectious Diseases (USAMRIID). Both
represent a significant endorsement of Recce’s
technology platform and underscore the potential
of its critical role in future military and civilian
infection control efforts.
In preclinical development, promising results
came from Recce’s Anti-Infective Research
Unit at Murdoch Children’s Research Institute,
yielding positive efficacy data against the WHOpriority pathogen Acinetobacter baumannii and
Mycobacterium abscessus in a respiratory tract
infection model. These pathogenic bacteria are
a major global health threat and Recce’s results
continue to validate the broad-spectrum potential
|of our compounds in treating drug-resistant
infections.
Global Recognition and
the Urgency of Addressing
AMR
This recognition underscores the global urgency
surrounding antimicrobial resistance (AMR), as
it continues to pose a growing threat to health
systems worldwide. Our work at Recce remains
steadfastly focused on delivering bold, sciencedriven solutions to address this challenge for
those who need it most.
Recce’s manufacturing infrastructure remains robust
and highly scalable. We continue to build on our
achievement of producing 5,000 GMP-grade doses
per week. Our manufacturing process is proprietary,
expandable in a fast and economical manner, and
well-positioned to meet the large-scale supply
demands of our current and upcoming clinical trials.
Our People and the Road
Ahead
Our team continues to grow in both talent and
capability. We have top-tier clinical, scientific,
and operational experts whose experience and
commitment are instrumental as we transition into
late-stage development and potential commercial
readiness.
With a diversified clinical pipeline, global recognition
and sufficient manufacturing capacity, Recce is
confident of achieving success for its immediate
milestones. FY26 is set to be another transformative
year as we push forward with our mission to
redefine infection treatment globally.
On behalf of the entire Recce team, I would like to
take this opportunity to express my gratitude and to
thank our shareholders, global clinical collaborators,
business partners, and dedicated team for their
continued support and belief in our shared vision.
Sincerely,
Dr John Pendergast
Executive Chairman
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
Recce’s leading position in the global infectious
disease landscape continues to be recognised at
the highest levels. The World Health Organization
(WHO) included our lead compound, R327, in its
Antibacterial Agents in Clinical and Preclinical
Development report endorsing the significance
and unique aspects of R327 since it is the only
compound in the report categorised as an energy
production disruptor (adenosine triphosphate
(ATP)), highlighting both the novelty of our
approach and the critical need it addresses.
Manufacturing and
Operational Readiness
5
Letter from
the CEO
Dear Shareholders,
It is with great pleasure that I present the development
and commercial initiatives undertaken by Recce
Pharmaceuticals over the financial year ending
30 June 2025.
We are proud of what Recce
has accomplished this year,
not only as a clinical-stage
innovator, but as a financially
disciplined, commercially
focused organisation.
In support of our strong clinical momentum, FY25
was a year of meaningful progress across funding,
regulatory approvals, intellectual property, and
strategic partnerships, each vital to building Recce
into a globally recognised anti-infective company.
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
6
Funding and Financial Support
Towards the end of the financial year the Company
concluded a successful A$15.8 million capital raise
(all from existing shareholders). The Company
also went on to secure ~A$11.49 million in nondilutive funding. This strong financial position with
the benefit of retaining the FY25 rebate of ~A$8.5
million (expected November 2025) sees an effective
~A$39.63 million cash runway.
Recce remains a highly efficient company fully
benefiting from the advantageous 43.5% Australian
Research and Development (R&D) Tax Incentive
rebate that provided us with A$6.75 million of nondilutive funding for FY24. Additionally, a Canadian
Scientific Research & Experimental Development
rebate of US$175,122 (A$271,987) was received
from the Canadian Government to help fund our
international research initiatives. The Company
was also pleased to be awarded US$2 million from
the US Department of Defense, accelerating the
development of R327G and evaluating it as a
gel-based treatment to rapidly resolve burn
wound infections.
These initiatives reflect the confidence of both
institutional and retail investors in our technology,
progress, and path ahead.
Intellectual Property and
Global Recognition
Recce’s intellectual property portfolio continues
to grow, protecting our innovation in key global
markets. During the reporting period, we achieved
the granting of patents for RECCE® anti-infectives
in Australia (Family 3), China (Family 4) and Japan
(Family 4). These milestones further solidify our
international protection and extend the commercial
runway of our synthetic anti-infective platform
beyond 2040.
Strategic Partnerships and
Collaborations
Recce remains committed to building a global
ecosystem of partners to support both clinical
execution and eventual commercial scale.
Among the most notable milestones this year
was our Memorandum of Understanding (MoU)
with PT Etana Biotechnologies in Indonesia.
Etana is a prominent player in Southeast Asia’s
biopharmaceutical landscape and a key contributor
to Indonesia’s national health agenda. This
collaboration represents a major step toward
commercial readiness in one of the world’s most
populous and rapidly developing healthcare
markets.
Our ongoing collaboration with the Murdoch
Children’s Research Institute in Melbourne resulted
in the establishment of a dedicated anti-infective
research unit. Preclinical studies conducted here
have already yielded promising data against
WHO-priority drug-resistant pathogens, reinforcing
the broad potential of our synthetic antibiotics.
On behalf of the management team, I would like
to thank our shareholders, partners, and dedicated
employees for their continued support and belief
in Recce’s mission. We look forward to delivering
further progress in FY26 and beyond.
James Graham
Managing Director & Chief Executive Officer
RECCE PHARMACEUTICALS ANNUAL REPORT 2024
We also continued to deepen relationships
with clinical research organisations and hospital
networks across Australia, supporting the scale-up
of our clinical trials and study coordination efforts.
We are proud of what Recce has accomplished
this year, not only as a clinical-stage innovator, but
as a financially disciplined, commercially focused
organisation. Our funding pipeline is strong, our
global presence is expanding, and our technology
is increasingly recognised for the impact it can have
on one of the greatest public health challenges of
our time.
7
Overview of
Company Activities
In FY25, Recce Pharmaceuticals made strong progress across its clinical,
preclinical as it advances its pipeline of synthetic anti-infectives targeting serious,
drug-resistant infections.
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
8
To support its pipeline, Recce secured A$15.8 million
in new equity capital and a secured ~A$11.49 million
in non-dilutive funding, ensuring a strong financial
foundation to pursue near-term regulatory and
commercial milestones.
Preparations are also underway to begin a Phase 3
trial with R327G in ABSSSI in Australia, reinforcing
Recce’s global regulatory strategy. This follows the
positive efficacy and safety data in a Phase II trial
for ABSSSI.
The Company received regulatory approvals for
a Registrational Phase III trial in Indonesia for
R327G in Diabetic Foot Infections, with an interim
analysis planned which could allow for expedited
commercialisation should the interim read-out meet
pre-specified safety and efficacy conditions.
Recce’s intravenous program has completed its
intravenous Phase I and I/II trials, with a Phase II trial
for UTI/urosepsis on track to begin in FY26.
Recce continued to progress its U.S. Department
of Defense burn wound program, with biopathogen
focused R&D work underway, furthermore Recce
has been selected for abstract presentation at the
2025 Military Health System Research Symposium
(MHSRS).
Program and
Route of Administration
Indications
Discovery
Preclinical
Phase I
Phase II
Phase III
Market
Diabetic Foot Infections
Phase 3 Indonesia (ASEAN)
R327 Tropical Gel
Registrational Trials
Acute Bacterial Skin
and Skin Structure Infections (DFI)
Australia (for US FDA submission)
R327 Intravenous
and Backups
cUTI/Hospital and Ventilator
Acquired Pneumonia
Other Seious Infections
Aerosol for Inhalation
Hospital Acquired Pneumonia
Ventilator-Associated Pneumonia
Serious Lung Infections
Civil Dept of
Defense Programs
Burn Wound Infections
Human Clinical Trials
R327 Topical Gel Programs
Registrational Phase 3 Clinical Trial
in Indonesia for Diabetic Foot Infections
Recce Pharmaceuticals has initiated its
Registrational Phase 3 clinical trial of R327G for
the treatment of Diabetic Foot Infection (DFI) in
Indonesia, following regulatory clearance from
the Indonesian Drug and Food Authority, Badan
POM. This pivotal study is a randomised, doubleblind, placebo-controlled trial, enrolling patients
across leading Indonesian hospitals, with two-thirds
receiving R327G and one-third receiving placebo.
TRIAL SNAPSHOT
Location: Indonesia
Program: Phase 3
Target: 300 patients
Interim analysis: after 100 patients
Goal: Accelerated approval H1 2026
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
The trial includes a protocol approved interim analysis after approximately 100 patients have been treated,
designed to assess early efficacy signals and support potential accelerated approval. This analysis reflects
confidence in the clinical performance of R327G, informed by strong results from the completed Phase II
study where 93% of patients achieved primary efficacy outcomes.
9
The trial is expected to conclude within a 12-month
timeframe, with a view to obtaining regulatory
approval and commercial launch in Indonesia in
the first half of calendar year 2026. Success in this
trial is anticipated to support further filings across
ASEAN member states, including Malaysia, Thailand,
Singapore, and the Philippines, where diabetic
complications and antimicrobial resistance represent
urgent public health challenges.
In addition to the Indonesian program, the Company
is planning to initiate another Phase 3 clinical trial
of R327G in DFI in Australia, conducted to a US
FDA regulatory standard for intended submission.
Reinforcing the product’s global development
pathway and supporting future submissions to
major international regulators.
Delegates from the Indonesia Food and Drug Authority (Badan POM), Indonesia Ministry of Health, Austrade, Investment
NSW, Department of Foreign Affairs & Trade and Recce Pharmaceuticals.
Phase II Acute Bacterial Skin and
Skin Structure Infections (ABSSSI)
Clinical Trial
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
10
During FY25, Recce Pharmaceuticals successfully
completed a Phase II clinical trial of its R327G for
the treatment of ABSSSI, including cases of DFI.
The study demonstrated compelling efficacy results,
achieving a 93% primary efficacy endpoint at day 14
and 86% clinical response by day 7, with no serious
adverse events reported. These results exceeded all
study objectives and reinforced R327G’s safety and
rapid-acting antibacterial properties.
Achieving a 93% efficacy
endpoint at day 14 with
no serious adverse events.
In response to the strong outcomes and positive engagement from clinical investigators, the trial received
Human Research Ethics Committee (HREC) approval to extend patient enrolment for the treatment of DFI.
Up to 20 additional DFI patients will be treated under the same open-label protocol, enabling further data
collection without delaying the initiation of Recce’s parallel Phase 3 trials in Indonesia and Australia.
The decision to expand access to R327G was driven
by medical need and the high recurrence rate of
DFI, with up to 40% of diabetic ulcers recurring
within the first year after healing. Investigators cited
R327G’s ability to deliver targeted topical treatment
without the side effects associated with systemic
antibiotics, positioning it as a promising alternative
for difficult-to-treat infections.
Together, the results from this Phase II study and
its ongoing extension support Recce’s accelerated
commercialisation pathway and provide a robust
clinical foundation as the Company advances toward
registrational trials in high-burden infection markets.
Successful clinical response
GLOBAL CHALLENGES
After 7 days of treatment
After 14 days of treatment
86%
93%
The rise of antibiotic-resistant
bacteria, particularly methicillinresistant Staphylococcus aureus
(MRSA), complicates treatment
strategies, underscoring the
need for the development of
new broad-spectrum antibiotics.
Department of Defence Burn Wound Program
In FY25, Recce Pharmaceuticals has significantly
progressed its U.S. Department of Defense
collaboration under the Military Burn Research
Program, focused on the development of R327G
for the treatment of burn wound infections in
military settings. Recce was awarded a peerreviewed USD$2M grant, one of only 3 recipients
and the only non-US entity to receive this grant
in the funding round and is advancing a series of
preclinical efficacy studies in rat and pig thermal
wound infection models, designed to support future
clinical deployment.
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
R327G is also being evaluated in hydrogel dressing
formats, offering an alternative to conventional
antimicrobial wound care by providing broadspectrum, synthetic anti-infective action without
the risk of resistance. This approach aligns with the
U.S. military’s need for fast-acting, field-deployable
therapeutics to manage trauma-related infections
and prevent complications such as sepsis.
11
Efficacy against high-priority
biothreat pathogens
In parallel, Recce has entered into an active research
partnership with the U.S. Army Medical Research
Institute of Infectious Diseases (USAMRIID) to test
R327 against high-priority biothreat pathogens,
reinforcing the platform’s dual-use potential in both
combat and biodefense contexts.
R327 has demonstrated significant
activity against multiple high-priority
bioterrorism pathogens.
BIOTERRORISM PATHOGENS
IDENTIFIED BY THE CDC
Highlighting the growing recognition of its
innovation, Recce was also accepted for a poster
presentation and abstract at MHSRS 2025 (Military
Health System Research Symposium), the premier
U.S. forum for military medical research. This
milestone marks further validation of R327G’s
potential to transform infection control in military
medicine.
Bacillus anthracis
Disease: (Anthrax)
Francisella tularensis
Disease: (Tularemia)
Burkholderia mallei
Disease: (Glanders)
Burkholderia
pseudomallei
Disease: (Melioidosis)
Yersinia pestis
Disease: (Plague)
R327 Intravenous (I.V.)
Following the successful completion of its Phase I
and Phase I/II clinical trials, Recce Pharmaceuticals
continues to advance the development of R327 in
I.V. formulation for the treatment of urinary tract
infections (UTIs) and urosepsis, a serious and often
life-threatening complication.
The Phase I trial demonstrated that R327 was safe
and well tolerated at escalating doses up to 6,000
mg delivered via 1-hour infusion, with no serious
adverse events reported. Pharmacokinetic analyses
confirmed that R327 concentrates in the urinary
tract, with urine levels up to 20 times higher than
in plasma, supporting its application as a targeted
therapy for urinary infections.
Clinical Trial Complete – Phase I/II
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
12
Assessment
Assessing R327 at faster administration rates (<1 hour)
Endpoint
Trial aimed at positioning R327 as first patient presentation ‘fast-infusion’
designed to stop any bacterial infection in its tracks in any medical setting
Subjects
Male and female subjects dosed
Initial Indication
Results from trial paves the way for R327 as a potential first-line treatment
for patients suffering from UTI/Urosepsis
US FDA Status
Qualified Infectious Disease Product designation - awarded by the US FDA in
2017 for R327 bacteraemia (broad-spectrum bacterial sepsis).
The subsequent Phase I/II trial further validated the compound’s safety and rapid bactericidal activity
in ex vivo studies. In these tests, R327-treated urine from trial participants was shown to effectively and
irreversibly eliminate Escherichia coli, a common cause of UTIs and sepsis.
15 min
20 min
R327 has achieved multiple ‘fast infusion’
time stamps in line with intended future
regulatory submissions.
1 hour
30 min
45 min
Building on this robust clinical and pharmacological
foundation, Recce is preparing for the initiation of
a full scale Phase II clinical trial in UTI/Urosepsis,
anticipated to commence in FY26. This trial will
assess the therapeutic efficacy of R327 I.V. in
patients with complicated UTIs and early-stage
urosepsis, where rapid treatment is critical.
The Company views this upcoming trial as a major
step forward in expanding R327’s utility beyond
topical applications and into systemic infections,
aligning with global priorities to address the growing
threat of antimicrobial resistance in hospital and
emergency care settings.
Preclinical Programs
Recce continues to expand its anti-infective pipeline through strategic preclinical research targeting
WHO-listed priority pathogens. Key studies conducted in collaboration with the Murdoch Children’s
Research Institute (MCRI) have provided strong evidence for the broad-spectrum potential R327 in
addressing serious, drug-resistant infections.
Acinetobacter baumannii (A. baumannii)
Study Details: A recent study conducted at Recce’s Anti-Infective Research
Unit within MCRI demonstrated significant intracellular bactericidal activity
of R327 against multidrug-resistant Acinetobacter baumannii, a WHO
critical-priority pathogen.
Results: R327 achieved a >6.5 log reduction (99.9999%) in intracellular
bacterial burden in human skin cells within 1 hour, reducing bacteria to
below the limit of quantification (BLOQ).
Study Details: Recce also validated R327’s potential against Mycobacterium
abscessus, a non-tuberculous mycobacteria (NTM) known for causing lung
infections in cystic fibrosis and immunocompromised patients.
Results: In preclinical models, R327 demonstrated greater efficacy than
clarithromycin, the current standard treatment, and showed no cytotoxicity
to host cells. R327 was successfully delivered via nebulisation in a mouse
lung infection model, showing strong efficacy without adverse effects.
These results position R327 as a promising therapeutic for NTM-related
lung and skin infections, offering a shorter, safer alternative to current
multi-drug regimens, which are often prolonged and poorly tolerated.
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
Mycobacterium abscessus (M. abscessus)
13
Conference
Engagement
Key Events with Investors, Key Opinion Leaders, and Global Conferences
The Company continued its presence at global conferences and interactions with Key Opinion Leaders
to increase investment opportunities and engagement within the sepsis and antimicrobial resistance
community.
Attending global investor and industry events has allowed the Company to expand its business
development programs and network with potential partners as well as broaden its investor base to
healthcare focused investors and international investors.
Pharmaceuticals
@reccepharma
See below the conferences and key media coverage the
Company participated in throughout the financial year.
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
14
Dr Graham Melrose
BSc (Hons), PhD, MBA, FRACI, CChem and FAICD
Acknowledgment of Recce Pharmaceuticals Founder
Recce Pharmaceuticals wishes to acknowledge the contributions of
Dr Graham Melrose, founder of Recce’s technology and a key figure in the
company’s mission to combat the global threat of antibiotic resistance.
Recce Pharmaceuticals wishes to acknowledge
the contributions of Dr Graham Melrose, founder
of Recce’s technology and a key figure in the
company’s mission to combat the global threat
of antibiotic resistance.
While Dr Melrose has formally stepped back
from day-to-day involvement, the legacy of his
scientific ingenuity and visionary leadership
continues to shape Recce’s trajectory.
We extend our appreciation for Dr Graham
Melrose and his unparalleled contribution to
Recce Pharmaceuticals and the wider biotech
community.
RECCE PHARMACEUTICALS ANNUAL REPORT 2025
Specialising in the fields of polymer chemistry
and infectious diseases, Dr Melrose has been
influential in impacting the global biotechnology
landscape. He founded Recce Pharmaceuticals
in 2006, bringing with him a vision to develop
next-generation anti-infectives capable of
addressing antimicrobial resistance. As the
inventor of RECCE® platform technology of
synthetic polymer anti-infectives, his scientific
insight and vision laid the foundation for the
company’s continued innovation and success.
Dr Melrose’s credentials include: BSc (Hons),
PhD, MBA, FRACI, CChem and FAICD. Prior to
founding Recce, he served as Executive Director
and Head of Research at Johnson & Johnson
(Australia) for eight years, overseeing global
responsibilities across the Asia-Pacific region.
He also held academic positions, including
Senior Lecturer in the Department of Applied
Organic Chemistry at the University of New
South Wales, and served as a visiting research
scientist at both Oxford and Munich Universities.
15
Board of Directors and
Management Personnel
Dr John Prendergast
Executive Chairman
BSc (Hons), MSc (UNSW),
PhD (UNSW), CSS (HU)
Dr Prendergast, based in the US, is a renowned executive
in the pharmaceutical industry. Currently serving as the
Chairman and Co-founder of Palatin Technologies, Inc.
(NYSE: PTN) and the Lead Director of Nighthawk
Biosciences (NYSE: HHWK), he brings over three decades
of expertise in the commercialisation of pharmaceutical
technologies.
Dr Prendergast has led the approval of three new drug
applications and played a pivotal role in the successful
sale of Vylessi® to Cosette Pharmaceuticals with USD $159
million in contingent, sales-based milestones, marking a
significant achievement in the pharmaceutical landscape.
James Graham
Managing Director and
Chief Executive Officer
BCom (Entrepreneurship), GAICD
Michele
Share your feedback
Discover